Who are LORAZEPAM's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Onfi, Romazicon, Prosom, Versed, Versed, Xanax.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl580.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

LORAZEPAM — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LORAZEPAM (LORAZEPAM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzodiazepine [EPC].

marketed Benzodiazepine [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

LORAZEPAM (LORAZEPAM).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LORAZEPAM TARGET	LORAZEPAM		marketed	Benzodiazepine [EPC]		1977-01-01
Onfi	CLOBAZAM	Lundbeck Pharms Llc	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	2011-01-01
Romazicon	FLUMAZENIL		marketed	Benzodiazepine Antagonist [EPC]	Gamma-aminobutyric acid receptor subunit alpha-5	1991-01-01
Prosom	ESTAZOLAM	Abbott	marketed	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-2/gamma-2	1990-01-01
Versed	midazolam	Generic (originally Roche)	marketed	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	marketed	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Xanax	alprazolam	Generic (originally Upjohn/Pfizer)	marketed	Benzodiazepine (triazolobenzodiazepine)	Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4	1981-10-16

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-01-18 — Versed · 9687495 · Formulation · US
2028-01-18 — Versed · 9289432 · Formulation · US
2028-01-18 — Versed · 8217033 · Formulation · US
2028-01-18 — Versed · 8809322 · Formulation · US
2028-01-18 — Versed · 9687495 · Formulation · US
2028-01-18 — Versed · 9289432 · Formulation · US
2028-01-18 — Versed · 8217033 · Formulation · US
2028-01-18 — Versed · 8809322 · Formulation · US
2038-06-20 — Versed · 10966990 · Formulation · US
2038-06-20 — Versed · 10966990 · Formulation · US
2039-09-05 — Onfi · 12403090 · Formulation · US
2039-09-05 — Onfi · 12290597 · Formulation · US
2040-01-31 — Onfi · 11541002 · Formulation · US

Sponsor landscape (Benzodiazepine [EPC] class)

Generic (originally Roche) · 2 drugs in this class
· 2 drugs in this class
Abliva AB · 1 drug in this class
Mallinckrodt · 1 drug in this class
Generic (originally Wyeth/Pfizer) · 1 drug in this class
Lundbeck Pharms Llc · 1 drug in this class
Abbott · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LORAZEPAM — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl580. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing